These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 12749507

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW.
    Br J Clin Pharmacol; 2003 Jan; 55(1):94-9. PubMed ID: 12534645
    [Abstract] [Full Text] [Related]

  • 24. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
    Martin PD, Schneck DW, Dane AL, Warwick MJ.
    Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
    [Abstract] [Full Text] [Related]

  • 25. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW.
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
    Lee D, Roh H, Son H, Jang SB, Lee S, Nam SY, Park K.
    Clin Ther; 2014 Aug 01; 36(8):1171-81. PubMed ID: 24976448
    [Abstract] [Full Text] [Related]

  • 28. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.
    J Clin Lipidol; 2012 Aug 01; 6(6):534-44. PubMed ID: 23312049
    [Abstract] [Full Text] [Related]

  • 29. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
    Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E.
    Clin Ther; 2003 Nov 01; 25(11):2822-35. PubMed ID: 14693307
    [Abstract] [Full Text] [Related]

  • 30. Treatment of hyperlipidaemia with fenofibrate and related fibrates.
    Filippatos T, Milionis HJ.
    Expert Opin Investig Drugs; 2008 Oct 01; 17(10):1599-614. PubMed ID: 18808320
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
    Li XN, Xu HR, Chen WL, Chu NN, Zhu JR.
    Clin Ther; 2010 Mar 01; 32(3):575-87. PubMed ID: 20399994
    [Abstract] [Full Text] [Related]

  • 32. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
    Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.
    Clin Drug Investig; 2010 Mar 01; 30(1):51-61. PubMed ID: 19995098
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
    Choi HY, Lim HS, Kim YH, Jeon HS, Kim MJ, Lee SH, Jung JH, Lee YK, Kim HJ, Bae KS.
    Curr Med Res Opin; 2015 Feb 01; 31(2):229-41. PubMed ID: 25350224
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
    Zhang W, Deng S, Chen XP, Zhou G, Xie HT, He FY, Cao D, Li YJ, Zhou HH.
    Clin Ther; 2008 Jul 01; 30(7):1283-9. PubMed ID: 18691987
    [Abstract] [Full Text] [Related]

  • 36. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
    Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D.
    J Clin Pharmacol; 2011 Mar 01; 51(3):378-88. PubMed ID: 20413454
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM, Wang H, Hao J, Lepist EI, Ray AS, Andrews J, Ling KH, Cheng A, Kearney BP, Ramanathan S.
    J Clin Pharmacol; 2014 Jun 01; 54(6):649-56. PubMed ID: 24375014
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.
    Roh H, Son H, Lee D, Chang H, Yun C, Park K.
    Clin Ther; 2014 Aug 01; 36(8):1159-70. PubMed ID: 25017182
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
    Trabelsi F, Bartůnek A, Vlavonou R, Navrátilová L, Dubé C, Tanguay M, Hauser T.
    Int J Clin Pharmacol Ther; 2012 Oct 01; 50(10):741-50. PubMed ID: 22762855
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.